Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli

Journal of Cellular Physiology

Volumn 227, Issue 4, 2012, Pages 1319-1325

  Fernando, Joan ^a   Sancho, Patricia ^a   Fernández Rodriguez, Conrado M ^b   Lledó, José L ^b   Caja, Laia ^a   Campbell, Jean S ^c   Fausto, Nelson ^c   Fabregat, Isabel ^a,d  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; BIM PROTEIN; CASPASE 3; CYCLIN D1; CYTOCHROME C; PROTEIN BAK; PROTEIN BAX; PROTEIN MCL 1; PUMA PROTEIN; SORAFENIB; SURVIVIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL SURVIVAL; CYTOSOL; DIPLOIDY; DRUG EFFECT; DRUG SENSITIZATION; ENZYME ACTIVATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; M PHASE CELL CYCLE CHECKPOINT; MITOCHONDRION; PRIORITY JOURNAL; S PHASE CELL CYCLE CHECKPOINT;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOCRINE COMMUNICATION; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIVER NEOPLASMS; PROTO-ONCOGENE PROTEINS; PYRIDINES; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855738060     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22843     Document Type: Article

References (45)

1. Andrisani OM, Studach L, Merle P. 2010. Gene signatures in hepatocellular carcinoma (HCC). Semin Cancer Biol 21:4-9.
2. Blechacz BR, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ. 2009. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology 50:1861-1870.
3. Caja L, Sancho P, Bertran E, Iglesias-Serret D, Gil J, Fabregat I. 2009. Overactivation of the MEK/ERK pathway in liver tumor cells confers resistance to TGF-{beta}-induced cell death through impairing up-regulation of the NADPH oxidase NOX4. Cancer Res 69:7595-7602.
4. Caja L, Sancho P, Bertran E, Fabregat I. 2010. Dissecting the effect of targeting the epidermal growth factor receptor on TGF-beta-induced-apoptosis in human hepatocellular carcinoma cells. J Hepatol In press.
5. Carr BI, Hayashi I, Branum EL, Moses HL. 1986. Inhibition of DNA synthesis in rat hepatocytes by platelet-derived type beta transforming growth factor. Cancer Res 46:2330-2334.
6. Cazanave SC, Mott JL, Elmi NA, Bronk SF, Werneburg NW, Akazawa Y, Kahraman A, Garrison SP, Zambetti GP, Charlton MR, Gores GJ. 2009. JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem 284:26591-26602.
7. Chen KF, Tai WT, Liu TH, Huang HP, Lin YC, Shiau CW, Li PK, Chen PJ, Cheng AL. 2010. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res 16:5189-5199.
8. de Juan C, Benito M, Alvarez A, Fabregat I. 1992. Differential proliferative response of cultured fetal and regenerating hepatocytes to growth factors and hormones. Exp Cell Res 202:495-500.
9. Fabregat I. 2009. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 15:513-520.
10. Finn RS. 2010. Development of molecularly targeted therapies in hepatocellular carcinoma: Where do we go now? Clin Cancer Res 16:390-397.
11. Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, Krammer PH, Walczak H. 2004. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 11:S86-S96.
12. Herrera B, Alvarez AM, Sanchez A, Fernandez M, Roncero C, Benito M, Fabregat I. 2001. Reactive oxygen species (ROS) mediates the mitochondrial-dependent apoptosis induced by transforming growth factor (beta) in fetal hepatocytes. FASEB J 15:741-751.
13. Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, Hosui A, Miyagi T, Tatsumi T, Ishida H, Li W, Kanto T, Hiramatsu N, Hayashi N. 2010. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology 52:1310-1321.
14. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A, Goh BC, Smith PD, Soo KC. 2010. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol 52:79-87.
15. Ito N, Kawata S, Tamura S, Takaishi K, Shirai Y, Kiso S, Yabuuchi I, Matsuda Y, Nishioka M, Tarui S. 1991. Elevated levels of transforming growth factor beta messenger RNA and its polypeptide in human hepatocellular carcinoma. Cancer Res 51:4080-4083.
16. Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, Nakano T, Suzuki A. 2000. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 31:1080-1085.
17. Kurosu T, Ohki M, Wu N, Kagechika H, Miura O. 2009. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res 69:3927-3936.
18. Lazaro CA, Croager EJ, Mitchell C, Campbell JS, Yu C, Foraker J, Rhim JA, Yeoh GC, Fausto N. 2003. Establishment, characterization, and long-term maintenance of cultures of human fetal hepatocytes. Hepatology 38:1095-1106.
19. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. 2006. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851-11858.
20. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. 2008. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390.
21. Luo JH, Ren B, Keryanov S, Tseng GC, Rao UN, Monga SP, Strom S, Demetris AJ, Nalesnik M, Yu YP, Ranganathan S, Michalopoulos GK. 2006. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology 44:1012-1024.
22. Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, Savic R, Hoshida Y, Lim KH, Melgar-Lesmes P, Yea S, Peix J, Deniz K, Fiel MI, Thung S, Alsinet C, Tovar V, Mazzaferro V, Bruix J, Roayaie S, Schwartz M, Friedman SL, Llovet JM. 2009. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 51:725-733.
23. Oberhammer FA, Pavelka M, Sharma S, Tiefenbacher R, Purchio AF, Bursch W, Schulte-Hermann R. 1992. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor beta 1. Proc Natl Acad Sci USA 89:5408-5412.
24. Ortiz C, Caja L, Sancho P, Bertran E, Fabregat I. 2008. Inhibition of the EGF receptor blocks autocrine growth and increases the cytotoxic effects of doxorubicin in rat hepatoma cells: Role of reactive oxygen species production and glutathione depletion. Biochem Pharmacol 75:1935-1945.
25. Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang DS, Lu YS, Hsu C, Cheng AL. 2009. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma. Clin Cancer Res 15:5820-5828.
26. Ou DL, Shen YC, Yu SL, Chen KF, Yeh PY, Fan HH, Feng WC, Wang CT, Lin LI, Hsu C, Cheng AL. 2010. Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 70:9309-9318.
27. Panka DJ, Wang W, Atkins MB, Mier JW. 2006. The Raf inhibitor BAY43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 66:1611-1619.
28. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. 2010. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140:197-208.
29. Rahmani M, Davis EM, Crabtree TR, Habibi JR, Nguyen TK, Dent P, Grant S. 2007. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol 27:5499-5513.
30. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, Jin Z, Liu YY, Dicker DT, Chiao PJ, Flaherty KT, Smith CD, El-Deiry WS. 2007. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 12:66-80.
31. Sanchez A, Alvarez AM, Benito M, Fabregat I. 1996. Apoptosis induced by transforming growth factor-beta in fetal hepatocyte primary cultures: Involvement of reactive oxygen intermediates. J Biol Chem 271:7416-7422.
32. Sun Q, Ming L, Thomas SM, Wang Y, Chen ZG, Ferris RL, Grandis JR, Zhang L, Yu J. 2009. PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells. Oncogene 28:2348-2357.
33. Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, Chen PJ, Chen KF. 2011. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol In press.
34. Tang W, Lazaro CA, Campbell JS, Parks WT, Katze MG, Fausto N. 2007. Responses of nontransformed human hepatocytes to conditional expression of full-length hepatitis C virus open reading frame. Am J Pathol 171:1831-1846.
35. Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W. 2009. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol 220:214-221.
36. Valdes F, Alvarez AM, Locascio A, Vega S, Herrera B, Fernandez M, Benito M, Nieto MA, Fabregat I. 2002. The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor Beta in fetal rat hepatocytes. Mol Cancer Res 1:68-78.
37. Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. 2010. Hepatocellular carcinoma: Novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 61:317-328.
38. 2-terminal kinase pathways. J Cell Physiol 224:112-119.
39. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. 2008. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129-3140.
40. Worns MA, Galle PR. 2010. Novel inhibitors in development for hepatocellular carcinoma. Expert Opin Investig Drugs 19:615-629.
41. Wullaert A, van Loo G, Heyninck K, Beyaert R. 2007. Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: Effects on liver homeostasis and beyond. Endocr Rev 28:365-386.
42. Yu J, Zhang L. 2008. PUMA, a potent killer with or without p53. Oncogene 27:S71-S83.
43. Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, Adjei AA. 2005. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY43-9006. Oncogene 24:6861-6869.
44. Zhang G, Park MA, Mitchell C, Hamed H, Rahmani M, Martin AP, Curiel DT, Yacoub A, Graf M, Lee R, Roberts JD, Fisher PB, Grant S, Dent P. 2008a. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res 14:5385-5399.
45. Zhang W, Konopleva M, Ruvolo VR, McQueen T, Evans RL, Bornmann WG, McCubrey J, Cortes J, Andreeff M. 2008b. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 22:808-818.